Also, Carreno et al. reported that immunization with a dendritic cell-based personalized vaccine targeting neoantigens and gp100 peptides in three melanoma patients, promoted a diverse neoantigen-specific T cell receptor repertoire in terms of both TCRVβ usage and clonal composition. The gene discussed is PMEL; the disease is melanoma.